Compare Heron Therapeutics Inc (HRTX) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Manulife Financial Corporation — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Manulife Financial Corporation trades at $42.78 (market cap $69.96B). The key difference: Manulife Financial Corporation is far larger — about 764.9× Heron Therapeutics Inc's market cap, and Manulife Financial Corporation pays a 3.14% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MFC | |
|---|---|---|
Market Cap | $91.46M | $69.96B |
Sector | Health | Financials |
52-Week High | $1.96 | $43.39 |
52-Week Low | $0.39 | $29.90 |
Enterprise Value | $189.36M | $66.52B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Manulife Financial (MFC) trades at $42.56, down 1.91% today but remains near 52-week highs. The stock shows strong fundamentals with revenue growth from $46.2B in 2024 to $53.0B in 2025 and consistent profitability (12.07% net margin). Technical indicators are mixed with bullish moving averages but overbought RSI levels. Recent Q1 2026 earnings missed expectations despite strong Asia performance, while analyst consensus remains bullish with 57% buy ratings.
MFC presents a compelling value case with reasonable valuation (P/E 17.75) and dividend yield support. Key opportunities include AI integration partnerships and Asia growth, though risks include wealth management outflows and regulatory scrutiny. The stock's current technical overbought condition suggests potential near-term consolidation before resuming upward trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
